TY - JOUR
T1 - Medication-related osteonecrosis of the jaw
T2 - an evidence-based 2025 position statement from a Korean multidisciplinary task force
AU - The Committee for the Korean Position Paper on Medication-Related Osteonecrosis of the Jaw
AU - Korean Society for Bone and Mineral Research
AU - Korean Association of Oral and Maxillofacial Surgeons
AU - Korean Association of Maxillofacial Plastic and Reconstructive Surgeons
AU - Korean Society of Osteoporosis
AU - Korean Endocrine Society
AU - Kim, Jin Woo
AU - Kong, Sung Hye
AU - Kim, Jae Young
AU - Kwak, Mi Kyung
AU - Kim, Jun Young
AU - Oh, Ji Hyeon
AU - Park, Hyung Youl
AU - Kim, Beomtaek
AU - Lee, Young Kyun
AU - Han, Jeong Joon
AU - Kim, Moon Young
AU - Choi, Yong Jun
AU - Kwon, Yong Dae
AU - Song, Kwang Sup
AU - Kim, Beom Jun
AU - Kim, Sun Jong
AU - Baek, Seung Hoon
AU - Lee, Dong Ock
AU - Choi, Han Seok
AU - Kim, Ha Young
AU - Kwon, Tae Geon
N1 - Publisher Copyright:
© 2025 The Korean Association of Oral and Maxillofacial Surgeons.
PY - 2025/12
Y1 - 2025/12
N2 - (J Korean Assoc Oral Maxillofac Surg 2025;51:333-353) With a rapidly aging population and increasing use of antiresorptive agents, medication-related osteonecrosis of the jaw (MRONJ) represents a growing clinical challenge worldwide. To address the need for tailored clinical guidance, a multidisciplinary task force was convened. Five Korean academ-ic societies—the Korean Society for Bone and Mineral Research, the Korean Association of Oral and Maxillofacial Surgeons, the Korean Association of Maxillofacial Plastic and Reconstructive Surgeons, the Korean Society of Osteoporosis, and the Korean Endocrine Society—collaborated to develop this position statement. The consensus was formulated through comprehensive reviews of literature, combined with three rounds of formal surveys to consolidate expert opinion on controversial topics. This position paper provides evidence-based clinical guidelines for the prevention, diagnosis, and management of MRONJ tailored to the Korean healthcare environment. The diagnostic criteria affirm the standard definition but add a provision for diagnosis based on clinical or radiographic evidence of necrotic bone, even if the traditional 8-week timeframe has not been met. The committee advocates for retaining Stage 0 in the staging system to emphasize early detection and preventive intervention. Key recommendations include prescrip-tive, drug-specific guidelines for prophylactic drug holidays (e.g., a 2-month pause for oral bisphosphonates; timing surgery 3-4 months after the last denosumab injection) to minimize MRONJ risk from dental procedures. This statement also provides a clear framework for therapeutic drug holidays in established MRONJ, carefully balancing the need for jaw healing against systemic fracture risk. For treatment, this statement advocates for early and active surgical intervention across all MRONJ stages, supported by evidence of superior long-term outcomes compared to conservative management. This position statement offers a unique, evidence-based Korean clinical practice guideline for managing MRONJ. It is intended to standardize care, reduce clinical confusion, and ultimately improve patient outcomes by providing a clear framework for decision-making.
AB - (J Korean Assoc Oral Maxillofac Surg 2025;51:333-353) With a rapidly aging population and increasing use of antiresorptive agents, medication-related osteonecrosis of the jaw (MRONJ) represents a growing clinical challenge worldwide. To address the need for tailored clinical guidance, a multidisciplinary task force was convened. Five Korean academ-ic societies—the Korean Society for Bone and Mineral Research, the Korean Association of Oral and Maxillofacial Surgeons, the Korean Association of Maxillofacial Plastic and Reconstructive Surgeons, the Korean Society of Osteoporosis, and the Korean Endocrine Society—collaborated to develop this position statement. The consensus was formulated through comprehensive reviews of literature, combined with three rounds of formal surveys to consolidate expert opinion on controversial topics. This position paper provides evidence-based clinical guidelines for the prevention, diagnosis, and management of MRONJ tailored to the Korean healthcare environment. The diagnostic criteria affirm the standard definition but add a provision for diagnosis based on clinical or radiographic evidence of necrotic bone, even if the traditional 8-week timeframe has not been met. The committee advocates for retaining Stage 0 in the staging system to emphasize early detection and preventive intervention. Key recommendations include prescrip-tive, drug-specific guidelines for prophylactic drug holidays (e.g., a 2-month pause for oral bisphosphonates; timing surgery 3-4 months after the last denosumab injection) to minimize MRONJ risk from dental procedures. This statement also provides a clear framework for therapeutic drug holidays in established MRONJ, carefully balancing the need for jaw healing against systemic fracture risk. For treatment, this statement advocates for early and active surgical intervention across all MRONJ stages, supported by evidence of superior long-term outcomes compared to conservative management. This position statement offers a unique, evidence-based Korean clinical practice guideline for managing MRONJ. It is intended to standardize care, reduce clinical confusion, and ultimately improve patient outcomes by providing a clear framework for decision-making.
KW - Bisphosphonates
KW - Denosumab
KW - Drug holiday
KW - Guideline
KW - Medication-related osteonecrosis of the jaw
KW - Osteoporosis
KW - Prevention
UR - https://www.scopus.com/pages/publications/105028767932
U2 - 10.5125/jkaoms.2025.51.6.333
DO - 10.5125/jkaoms.2025.51.6.333
M3 - Article
AN - SCOPUS:105028767932
SN - 2234-7550
VL - 51
SP - 333
EP - 353
JO - Journal of the Korean Association of Oral and Maxillofacial Surgeons
JF - Journal of the Korean Association of Oral and Maxillofacial Surgeons
IS - 6
ER -